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Telomeres, telomerase, and shelterins
Telomeres form a special heterochromatic structure at the end 
of linear chromosomes that protects them from degradation and 
DNA repair and recombination activities. Thus, telomeres are 
essential to ensure chromosome stability (Blasco, 2005; Palm 
and de Lange, 2008). Mammalian telomeres comprise several 
kilobases, between 10 and 15 kb in humans and 25 and 50 kb in 
mice, of tandem TTA GGG DNA repeats (Blasco, 2005). Telo-
meres are characterized by the presence of a 30–400-nucleo-
tide-long 3′ overhang of a G-rich strand, known as the G-strand 
overhang. The G-strand overhang can fold back and invade the 
double-stranded telomeric region, forming the so-called T-loop 
and generating a displacement loop, or D-loop. The T-loop 
structure has been proposed to protect chromosome ends from 
degradation and DNA repair activities as well as from telomer-
ase activity (Fig. 1, A and B; Griffith et al., 1999; Doksani et al., 
2013). Telomeres are bound by a specialized complex known 
as shelterin that has crucial functions in telomere length regu-
lation and in the protection of telomeres from the DNA dam-
age response (DDR) by masking the chromosome ends from 
the DNA repair machinery through repression of the ATM and 
ATR signaling pathways (Palm and de Lange, 2008; Fig. 1 C). 
The shelterin complex is composed of six proteins: telomeric 
repeat binding factors 1 and 2 (TRF1 and TRF2), TRF1- 
interacting protein 2 (TIN2), protection of telomeres protein 1 
(POT1), TIN2, POT1-interacting protein (TPP1), and repressor/
activator protein 1 (RAP1; Fig. 1 C; de Lange, 2005; Martínez 
and Blasco, 2010, 2011).
Telomeres shorten with each cell division as a result of 
the incomplete replication of linear DNA molecules by conven-
tional DNA polymerases, which is called the end-replication 
problem (Watson, 1972; Olovnikov, 1973). Telomerase com-
pensates for telomere attrition through de novo addition of TTA 
GGG repeats onto chromosome ends in those cells where it is 
normally expressed, such as pluripotent stem cells and adult 
stem cell compartments (Liu et al., 2007; Flores et al., 2008; 
Marion et al., 2009). Telomerase is composed of a reverse tran-
scriptase subunit (TERT) as well as an associated RNA compo-
nent (Terc), which is used as a template for the de novo addition 
of telomeric repeats (Fig. 1 C; Greider and Blackburn, 1985). 
Although telomerase is expressed in adult stem cell compart-
ments, this is not sufficient to counteract telomere attrition 
associated with cell division throughout life, and therefore telo-
meres shorten with age in vitro and in vivo (Harley et al., 1990; 
Hastie et al., 1990; Lindsey et al., 1991; Collado et al., 2007; 
Liu et al., 2007; Flores et al., 2008; Marion et al., 2009). This 
progressive telomere shortening eventually leads to critically 
short telomeres that can impair the regenerative capacity of tis-
sues and has been proposed as one of the molecular hallmarks 
of aging (López-Otín et al., 2013). In mice, it has been shown 
that the rate of increase in the percentage of short telomeres, 
rather than the rate of telomere shortening throughout life, is a 
significant predictor of life span (Vera et al., 2012). Shortened 
telomeres induce a DDR that leads to a growth arrest, during 
which cells attempt to repair the damage and, if DNA damage 
is irreparable, triggers replicative senescence (Zou et al., 2004; 
Fumagalli et al., 2012). Senescent cells progressively accumu-
Telomeres, the protective ends of linear chromosomes, 
shorten throughout an individual’s lifetime. Telomere 
shortening is proposed to be a primary molecular cause 
of aging. Short telomeres block the proliferative capacity 
of stem cells, affecting their potential to regenerate tissues, 
and trigger the development of age-associated diseases. 
Mutations in telomere maintenance genes are associated 
with pathologies referred to as telomere syndromes, in-
cluding Hoyeraal-Hreidarsson syndrome, dyskeratosis 
congenita, pulmonary fibrosis, aplastic anemia, and liver 
fibrosis. Telomere shortening induces chromosomal insta-
bility that, in the absence of functional tumor suppressor 
genes, can contribute to tumorigenesis. In addition, muta-
tions in telomere length maintenance genes and in shel-
terin components, the protein complex that protects 
telomeres, have been found to be associated with differ-
ent types of cancer. These observations have encouraged 
the development of therapeutic strategies to treat and pre-
vent telomere-associated diseases, namely aging-related 
diseases, including cancer. Here we review the molecular 
mechanisms underlying telomere-driven diseases and 
highlight recent advances in the preclinical development 
of telomere-targeted therapies using mouse models.
Telomere-driven diseases and telomere-targeting 
therapies
Paula Martínez and Maria A. Blasco
Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre, Madrid E-28029, Spain
© 2017 Martínez and Blasco This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http ://www .rupress .org /terms /). After six months it is available under 
a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International 
license, as described at https ://creativecommons .org /licenses /by -nc -sa /4 .0 /).
Correspondence to Maria A. Blasco: mblasco@cnio.es
Abbreviations used: 6-thio-dG, 6-thio-2′-deoxyguanosine; AAV, adeno-associ-
ated vector; ALT, alternative lengthening of telomeres; BM, bone marrow; DC, 
dyskeratosis congenita; DDR, DNA damage response; HHS, Hoyeraal-Hreidars-
son syndrome; HSPC, hematopoietic stem/progenitor cell; IPF, idiopathic PF; 
MC, mitotic catastrophe; PF, pulmonary fibrosis; TPE, telomere position effect.
on October 2, 2019jcb.rupress.org Downloaded from 
http://doi.org/10.1083/jcb.201610111Published Online: 2 March, 2017 | Supp Info: 
JCB • Volume 216 • NumBer 4 • 2017876
late during life and secrete factors that influence age-associated 
diseases (Tchkonia et al., 2013). Indeed, senescence has been 
proposed as a mechanism that evolved to protect from cancer, 
with the drawback of promoting age-associated diseases (Shay, 
2016). Therapeutic interventions based on either chemical acti-
vators of telomerase or telomerase-based gene therapy are cur-
rently being investigated in mouse models for their potential to 
improve health and extend life span, and as a treatment for short 
telomere syndromes (Bernardes de Jesus et al., 2011; Bär et al., 
2014, 2015; Bär and Blasco, 2016).
Aging-associated diseases and 
telomeropathies
Telomeres shorten progressively throughout an individual’s life-
time (Cawthon et al., 2003; López-Otín et al., 2013; Sanders and 
Newman, 2013). Telomere attrition in stem cell compartments 
impairs their tissue and self-renewal capacity and is considered 
to be one of the primary molecular causes of aging and the onset 
of aging-associated diseases (Flores et al., 2005; Sharpless and 
DePinho, 2007). The first demonstration that telomere shorten-
ing is at the origin of age-related pathologies and is a determi-
nant of longevity came from the study of telomerase-deficient 
mice, which show premature aging phenotypes in both low- 
proliferating (heart, brain) and high-proliferating compartments 
(bone marrow [BM], gut, skin, and testis; Blasco et al., 1997; 
Lee et al., 1998; Herrera et al., 1999; Leri et al., 2003; Ferrón et 
al., 2004). Telomere shortening with age has also been observed 
in several mouse stem cell compartments from different tissues 
independently of high or low tissue proliferation rates (Flores 
et al., 2008). Telomerase-deficient mice show a worsening of 
phenotypes with increasing mouse generations owing to inher-
ited progressively shorter telomeres, with the later generations 
showing severe phenotypes and premature death at pre-repro-
ductive ages (Lee et al., 1998; Herrera et al., 1999; García-Cao 
et al., 2002). This phenomenon first indicated genetic antici-
pation associated with telomerase deficiency. However, and in 
support of critical telomere shortening being a determinant of 
aging and longevity, increased TERT expression in the context 
of cancer-resistant transgenic mice was sufficient to delay aging 
and extend mouse longevity by 40% (Tomás-Loba et al., 2008). 
More recently, these findings have been translated into a po-
tential therapeutic strategy by using adeno-associated vectors 
(AAVs) to transiently activate telomerase in adult tissues (Ber-
nardes de Jesus et al., 2012; Bär et al., 2014). Telomeropathies 
or telomere syndromes develop when telomere attrition occurs 
prematurely as a consequence of germline mutations in genes 
coding for factors involved in telomere maintenance and repair 
(Table 1). Human telomeropathies are mainly associated with 
Hoyeraal-Hreidarsson syndrome (HHS), dyskeratosis congen-
ita (DC), aplastic anemia, and pulmonary and liver disease and 
Figure 1. The shelterin complex and the structure of telomeres. (A) Representative image of a metaphasic chromosome stained with DAPI (blue) and the 
telomeric DNA–specific peptide nucleic acid probe (yellow). (B) Schematic model of the shelterin complex bound to a telomere in a T-loop configuration. 
Telomeres contain a double-stranded region of TTA GGG repeats and a 150–200-nucleotide-long single-stranded DNA overhang of a G-rich strand. The 
G-strand overhang (gray) invades the telomeric double-stranded DNA region to form a protective T-loop, with a displacement D-loop at the invasion site. 
(C) Schematic representation of telomere-bound proteins, the shelterin complex, and telomerase. The shelterin complex is composed of the telomeric repeat 
binding factor 1 (TRF1, also known as TERF1), TRF2 (also known as TERF2), repressor-activator protein 1 (RAP1, also known as TERF2IP1), POT1-TIN2 
organizing protein (TPP1, also known as ACD), TIN2 (also known as TIFN2), and protection of telomeres protein 1 (POT1). TRF1, TRF2, and POT1 bind 
directly to telomeric DNA repeats, with TRF1 and TRF2 binding to telomeric double-stranded DNA and POT1 to the 3′ single-stranded G-overhang. TIN2 
binds TRF1 and TRF2 through independent domains and recruits the TPP1–POT1 complex, constituting the bridge among the different shelterin components. 
Telomerase is a two-partner enzyme, the catalytic subunit (TERT) and the RNA template (TERC), that recognizes the 3′-OH at the end of the G-strand over-
hang and elongates the telomere.
Telomeres as therapeutic targets • martínez and Blasco 877
are nowadays considered more as a spectrum disorder than dis-
tinct diseases (see Clinical features of telomeropathies; Holo-
han et al., 2014; Stanley and Armanios, 2015). Although these 
diseases show a wide and complex range of clinical symptoms, 
all of them are characterized by presenting with critically short 
telomeres. The age of onset and the severity of clinical manifes-
tations vary among individuals. These syndromes are character-
ized by premature loss of the regenerative capacity of tissues, 
affecting tissues with both high and low proliferation rates (Ar-
manios and Blackburn, 2012; Holohan et al., 2014). As in mice, 
disease anticipation is also found in human families with telo-
mere syndromes, with the mutation generally first manifesting 
in adults with pulmonary fibrosis (PF), and the more severe phe-
notypes appearing in pediatric populations (immunodeficiency) 
and young adults (aplastic anemia) from the next generations 
(Armanios and Blackburn, 2012).
In addition to telomere-mediated replicative senescence, 
telomere length can have an impact on human diseases by 
regulating gene expression through telomere position effects 
(TPEs). TPEs involve the spreading of telomeric heterochroma-
tin to silence nearby genes. In human cells, it has been shown 
that gene expression is affected by telomere length (Stadler et 
al., 2013; Robin et al., 2014). In particular, genes located near 
the telomere at chromosome 4q are progressively up-regulated 
with decreasing telomere length, and this occurs long before 
terminal telomere shortening would induce replicative senes-
cence (Stadler et al., 2013). Interestingly, among the genes an-
alyzed, the effect of TPE is most prominent with DUX4, the 
one located nearest to the 4q telomere. Expression of DUX4, 
encoding a toxic double-homeobox protein, has been linked to 
facioscapulohumeral muscular dystrophy, a disease presenting 
with progressive atrophy and weakness of the facial, scapular, 
and upper arm muscles (Stadler et al., 2013). This disease has 
highly variable clinical manifestation, and delayed onset that 
can be explained by age-associated telomere shortening (Stadler 
et al., 2013). Thus, facioscapulohumeral muscular dystrophy 
constitutes the first human disease to demonstrate a potential 
contribution of TPE to the age-associated diseases.
Mouse models for PF, aplastic anemia, 
DC, and HHS
The study of mouse models genetically deficient in telomerase 
and telomeric proteins has been crucial to understanding the role 
of telomere biology in human telomeropathies. In particular, 
the telomerase knockout, Pot1 knockout, and Trf1 conditional 
knockout mouse models have recently served as proofs-of-prin-
ciple of the causal role of DNA damage stemming from dys-
functional telomeres in DC, idiopathic PF (IPF), and aplastic 
anemia (see text box; Hockemeyer et al., 2008; He et al., 2009; 
Martínez et al., 2009b; Beier et al., 2012). Recently, mutant 
mice expressing p53 lacking the C-terminal domain, a protein 
that is not directly involved in telomere maintenance, have been 
shown to be remarkable models for human telomeropathies, in 
particular for HHS (see text box; Simeonova et al., 2013).
Aplastic anemia mouse models
The aplastic anemia phenotypes in mouse (see text box) are 
provoked either by partially depleting TRF1 in the BM stem 
Table 1. Genes known to cause telomeropathies when defective, as well as the telomere-related processes and protein complexes in which they are involved
Process/protein complex Genes Telomeropathies
Telomerase core components TERC             DC, IPF, aplastic anemia, liver disease
TERT             DC, HHS, IPF, aplastic anemia, liver disease
Telomerase biogenesis DKC1             DC, HHS, IPF, aplastic anemia
NOP10             DC, IPF, aplastic anemia
NHP2             DC, IPF, aplastic anemia
Telomerase trafficking TCBA1             DC
Shelterin components TIN2             DC, HHS
TPP1             DC, HHS, aplastic anemia
Telomeric DNA synthesis RTEL1             HHS, IPF
CTC1             DC
TERC RNA processing PARN             DC, IPF
NAF1             IPF
The diseases found associated with the mutated genes are indicated (Calado et al., 2009a; Holohan et al., 2014; Glousker et al., 2015; Stanley and Armanios, 2015; Stanley 
et al., 2016).
Clinical features of telomeropathies
Aplastic anemia: Aplastic anemia is a BM failure state characterized by low blood counts and an insufficiency of hematopoietic cells in the BM (Fogarty et 
al., 2003).
Idiopathic pulmonary fibrosis (IPF): IPF is characterized by cough, dyspnea, impaired gas exchange, and reduced lung volume. Pathologically, there is 
patchy fibrosis of the lungs and interstitial inflammation, normal lung alternating with fibrosis, inflammation, and collagen deposition (Armanios et al., 
2007).
Liver disease: Liver disease associated with telomere shortening consists of mainly fibrosis with inflammation and nodular regenerative hyperplasia, a lead-
ing cause of noncirrhotic portal hypertension (Calado et al., 2009a).
Dyskeratosis congenita (DC): DC is classically diagnosed by the presence of the mucocutaneous triad of nail dysplasia, skin pigmentation, and oral leuko-
plakia or the presence of one feature of the triad in combination with BM failure and two other DC-associated findings. Patients with DC are at very high 
risk of BM failure, PF, liver fibrosis, stenosis, premature hair graying, leukemia, and squamous cell cancer of the head, neck, or anogenital regions (Ballew 
and Savage, 2013).
Hoyeraal-Hreidarsson syndrome (HHS): HHS is a multisystem genetic disorder characterized by very short telomeres (less than first percentile for age) and 
is considered a clinically severe variant of DC. Patients with HHS present in early childhood with cerebellar hypoplasia, microcephaly, immunodeficiency, 
BM failure, and intrauterine growth retardation. The DC-associated mucocutaneous triad is also a trait of HHS (Glousker et al., 2015).
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cell and progenitor compartments (hematopoietic stem/pro-
genitor cells [HSPCs]) or by transplanting irradiated wild-
type mice with BM from late-generation telomerase-deficient 
Tert knockout mice presenting with short telomeres (Beier et 
al., 2012; Bär and Blasco, 2016). Partial depletion of the Trf1 
gene in the BM causes a persistent DDR at telomeres that leads 
to a fast clearance of those HSPCs lacking TRF1. Compensa-
tory hyperproliferation of the remaining HSPCs to regenerate 
the BM results in a concomitant rapid attrition of telomeres 
(Beier et al., 2012). The short telomeres in BM of both mouse 
models faithfully recapitulate human acquired and congenital 
forms of aplastic anemia characterized by peripheral pancyto-
penia and marrow hypoplasia.
PF mouse models
Among the telomere syndromes, IPF is the most common con-
dition associated with telomere dysfunction in humans (see 
text box; Armanios and Blackburn, 2012). Mutations in telo-
mere genes have been found in up to 25% of familial and 1–3% 
of sporadic IPF patients (Armanios et al., 2007; Alder et al., 
2008; Cogan et al., 2015; Kannengiesser et al., 2015; Stuart et 
al., 2015; Stanley et al., 2016). Sporadic cases of IPF, not as-
sociated with mutations in telomere maintenance genes, also 
show shorter telomeres compared with age-matched controls, 
with 10% of the patients showing telomeres as short as those 
of the telomerase mutation carriers (Alder et al., 2008). In spite 
of PF and emphysema being the most frequent manifestations 
of telomere defects in humans, telomerase-deficient mice with 
critically short telomeres do not spontaneously develop pul-
monary disease. Telomere dysfunction in telomerase-deficient 
mice induces senescence in alveolar progenitor cells and re-
capitulates the regenerative defects, inflammatory responses, 
and susceptibility to injury that are characteristic of human 
telomere-mediated lung disease, although no IPF was reported 
in these mouse models (Alder et al., 2015a). Exposure to ciga-
rette smoke, which is known to accelerate PF onset in humans, 
induces emphysema but not PF in telomerase-deficient mice 
(Alder et al., 2011). These findings suggested that additional 
damages, or a telomere damage of higher severity, might be re-
quired for PF onset in mice. This was demonstrated in work 
from our laboratory, whereby we generated two independent 
mouse models that develop PF. In one of them, treatment of 
late-generation telomerase-deficient mice presenting short telo-
meres with low doses of bleomycin, which normally does not 
lead to PF in wild-type mice, results in full-blown progressive 
PF in telomerase-deficient mice (Povedano et al., 2015). In the 
second mouse model, severe PF was developed by induction 
of telomere dysfunction in the absence of telomere shortening 
specifically in the lungs, by genetically deleting the shelterin 
component Trf1 from epithelial type II alveolar cells (Pove-
dano et al., 2015). In both models, we observed activation of 
the p53/p21 and p19ARF pathways, resulting in cell senes-
cence and apoptosis. Both TERT and TRF1 deficiencies were 
previously shown to lead to a decreased ability of stem cells to 
regenerate tissues (Flores et al., 2005; Schneider et al., 2013). 
Thus, increased lung cell loss associated with severe telomere 
dysfunction triggers aberrant lung healing by fibroblasts, even-
tually leading to scar formation and PF. We showed that a DNA- 
damaged burden above a certain threshold, combined with de-
fective stem cell regeneration ability, lead to the development of 
PF (Povedano et al., 2015). The TRF1-interacting shelterin pro-
tein TIN2 has also been found to be mutated in telomere syn-
dromes (Savage et al., 2008; Alder et al., 2015b; Hoffman et al., 
2016). Interestingly, a TIN2 mutation in its TRF1-interacting 
domain has recently been identified in a patient with sporadic 
PF who showed normal telomere length in the peripheral blood 
compartment, underlining the importance of telomere protec-
tion proteins and not only telomere length in human telomere 
syndromes (Hoffman et al., 2016).
DC and HHS mouse models
DC and HHS share a common etiology, are typically caused by 
germline mutations in telomere biology genes, and are charac-
terized by very short telomeres (see text box; Glousker et al., 
2015). In mice, double deletion of Pot1b and Terc gives rise to 
some DC features such as hyperpigmentation and BM failure 
(Hockemeyer et al., 2008; He et al., 2009). HHS is considered 
a clinically severe variant of DC (Glousker et al., 2015). Telo-
meres in HHS patients are shorter than those of age-matched 
patients with classic DC (Alter et al., 2012). Although exceed-
ingly short telomeres are considered the main cause of HHS, 
it is likely that other telomeric or nontelomeric defects also 
contribute to the pathology of HHS, perhaps distinguishing it 
from DC (Glousker et al., 2015). Indeed, to our knowledge, the 
only mouse mutant that faithfully models human HHS does not 
harbor mutations in any of the known telomere maintenance 
genes associated with these diseases, but rather a mutation in 
TP53 gene (Simeonova et al., 2013). p53Δ31/Δ31 mice, homozy-
gous mutant mice expressing a truncated p53 protein lacking 
the C-terminal domain, suffer from aplastic anemia and PF as 
well as other phenotypic traits associated with DC and its severe 
variant, HHS (Simeonova et al., 2013). Thus, p53Δ31/Δ31 mice are 
born at the expected Mendelian ratio, but most die 14–43 d after 
birth because of aplastic anemia and heart failure, develop PF, 
and present cutaneous hyperpigmentation, nail dystrophy, and 
oral leukoplakia as in DC. In addition, some mice also present 
HHS features such as small size, hypogonadism, and cerebel-
lar hypoplasia. The p53Δ31 protein shows increased p53 activity 
leading to down-regulation of genes involved in telomere me-
tabolism such as Dkc1, Rtel1, Tin2, and Trf1, thereby explaining 
the appearance of phenotypes related to human telomere syn-
dromes (Simeonova et al., 2013).
Therapeutic strategies in the treatment of 
telomere syndromes
Despite the growing understanding of the molecular defects as-
sociated with telomeropathies, the only current interventions to 
treat these diseases involve organ transplantation; i.e., BM, liver, 
and lung (Holohan et al., 2014; Stanley and Armanios, 2015). 
Although organ transplantation improves the physical condi-
tion of patients, it does not address the underlying cause of the 
symptoms, which is short telomeres. Patients diagnosed with 
interstitial lung disease presenting with short telomeres also 
showed subclinical BM and liver abnormalities, in some cases 
in the absence of clinical manifestations in peripheral blood 
count and liver dysfunction (George et al., 2015). These ob-
servations clearly favor a telomerase-activating therapy against 
other alternatives, such as organ transplant for the treatment of 
telomeropathies, because it also addresses the molecular defects 
of other affected organs. Indeed, the use of telomerase activators 
in the treatment of aging-associated conditions has raised com-
mercial interest. Among telomerase chemical activators, TA-
65, a small molecule derived from Astragalus membranaceus 
extracts, is the most widely studied. The telomerase activator 
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TA-65 has been shown to lead to moderate telomere lengthen-
ing and improvement of some aging-related parameters in mice 
and humans, although no effect on longevity has been observed 
(Fig. 2; Bernardes de Jesus et al., 2011; Harley et al., 2013). In 
addition, androgen therapy has been applied as a treatment for 
aplastic anemia for many years without knowing its mechanism 
of action (Fig. 2; Shahidi and Diamond, 1961; Jaime-Pérez et 
al., 2011). It was subsequently reported that sex hormones ac-
tivate TERT transcription (Calado et al., 2009b). Indeed, tes-
tosterone therapy in mice suffering from aplastic anemia was 
shown to up-regulate telomerase expression, rescue telomere 
attrition, and extend the life span of these mice (Fig. 2; Bär et 
al., 2015). In humans, administration of a synthetic androgen, 
danazol, to patients with telomeropathies resulted in telomere 
elongation in circulating leukocytes in association with hema-
tologic improvement (Townsley et al., 2016). However, endog-
enous telomerase reactivation strategies are applicable only in 
those clinical cases not associated with mutations in telomere 
maintenance genes such as TERT or TERC. In this regard, ther-
apeutic interventions based on telomerase-based gene therapy 
are currently being investigated in mouse models for their po-
tential to improve health and extend life span, and as a treatment 
for short telomere syndromes (Bär and Blasco, 2016).
We have developed a therapeutic strategy by using AAVs 
to transiently activate telomerase in adult tissues (Fig. 2; Ber-
nardes de Jesus et al., 2012; Bär et al., 2014). Treatment with 
Tert gene therapy using nonintegrative, replication-incompe-
tent AAV9 vectors of adult mice was able to delay aging and 
increase longevity by decreasing age-related pathologies such 
as osteoporosis and glucose intolerance, as well as neuromus-
cular and cognitive decline. Furthermore, the onset of cancer 
was delayed in the TERT-treated mice (Bernardes de Jesus et 
al., 2012). Interestingly, AAV9-Tert delivery specifically to the 
heart was sufficient to significantly increase mouse survival and 
heart function upon myocardial infarction. AAV9-Tert after in-
farct treatment led to lower fibrotic scarring of the heart and 
increased cardiac myocyte proliferation concomitant with tran-
scriptional changes suggestive of a regenerative signature (Bär 
et al., 2014). These findings support the notion that telomere 
shortening is at the origin of age-related diseases and that, by 
reverting this process with telomerase expression, it is possible 
to delay and more effectively treat age-associated pathologies, 
such as cardiovascular diseases. In addition, TERT gene ther-
apy is particularly attractive for the clinical treatment of human 
telomere syndromes associated with telomerase mutations and 
short telomeres. Indeed, by using the mouse preclinical model 
of aplastic anemia provoked by short telomeres in the BM, we 
demonstrate that AVV9-Tert rescues aplastic anemia and mouse 
survival by inducing telomere lengthening in peripheral blood 
and BM cells as well as increasing blood counts (Bär et al., 
2016). We are currently investigating the feasibility of AVV9-
Tert therapy in the treatment of PF, with positive results so far 
(unpublished data). An alternative nonintegrative method to 
transiently express TERT based on TERT mRNA delivery into 
human cells in culture has been developed, although it has not 
yet been tested in vivo (Fig. 2; Ramunas et al., 2015).
Telomerase activation strategies should be taken with cau-
tion given their potential off-target effects and their ability to 
promote cancer (Bär and Blasco, 2016). Nevertheless, recent 
data from our group demonstrated that chimeric mice pre-
senting hyperlong telomeres showed neither disadvantageous 
effects nor enhanced predisposition for cancer development 
compared with control chimeric mice presenting normal telo-
mere length, indicating that long telomeres do not cause nega-
tive consequences to the organism (Varela et al., 2016). Indeed, 
in chimeric mice with hyperlong telomeres, cells in compart-
ments with high rates of renewal retain longer telomeres and 
accumulate fewer short telomeres, less DNA damage burden, 
and lower levels of p53 with age (Varela et al., 2016). Thus, up 
to date experimental data in preclinical settings provide proof 
Figure 2. Natural factors and therapeutic interventions affecting telomere-mediated diseases. Telomere shortening naturally occurs as a consequence of 
cell division throughout life, whose pace can be influenced by genetic and environmental factors. Shortened unprotected telomeres elicit a DDR that induces 
cellular senescence, impacting the regenerative capacity of tissues and giving rise to a whole range of age-associated diseases as well as the so-called 
telomeropathies, in which tissue degeneration occurs prematurely as a consequence of inherited defects in telomere maintenance. Several therapeutic 
interventions are being assessed to counteract telomere shortening: among others, chemical activators of telomerase (TA-65), activators of the telomerase 
reverse transcription (TERT) transcription (sex hormones), intracellular administration of TERT mRNA, and telomerase gene therapy (AAV9-TERT). Sponta-
neous mutations that activate telomerase expression or ALT result in telomere lengthening that, if occurring in genetically unstable checkpoint deficient cells, 
allows them to divide unlimitedly and eventually become cancer cells. Several therapeutic strategies based on chemical induction of telomere dysfunction 
have been assessed as anticancer therapies. Among others, we highlight the use of a chemical inhibitor of telomerase (imetelstat), a nucleoside analogue 
(6-thio-dG), and the use of molecules that inhibit shelterin components.
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of concept for the viability of telomerase activation strategies 
to counteract telomere shortening and its associated conse-
quences. In particular, the use of TERT gene therapy consti-
tutes a promising candidate in the prevention and treatment 
of human telomeropathies mediated by TERT mutations and 
deserves further research efforts for clinical implementation. 
It should be noted that TERT gene therapy in the treatment of 
telomeropathies mediated by mutations in other genes associ-
ated with telomere metabolism (TERC, DKC1, NOP10, NHP2, 
TCAB1, TIN2, TPP1, RTEL1, CTC1, PARN, and NAF1) may, 
however, not be effective. 
Telomeres and malignant transformation
Telomere shortening throughout life is a natural consequence of 
cell division because of the end replication problem, replication 
fork collapse, oxidative stress, and nucleolytic processing. Crit-
ically shortened telomeres trigger replicative senescence that 
causes stem cell dysfunction and inflammation, in turn causing 
aging-associated diseases (Fig. 3 A; Jafri et al., 2016). In the 
situation of acquired germline mutations in genes coding for 
factors involved in telomere maintenance and repair, telomere 
shortening is accelerated, and replicative senescence occurs 
prematurely, giving rise to telomeropathies (Fig. 3 B; Holohan 
et al., 2014). In mammalian cells, replicative senescence can be 
bypassed by acquisition of loss-of-function mutations in tumor 
suppressor genes that permit further proliferation during a pe-
riod of time that has been named the extended life span period 
(Fig. 3 C; Wright and Shay, 1992; Shay and Wright, 2005; Shay, 
2016). Proliferation of premalignant cells during the extended 
life span period results in further telomere shortening. Even-
tually, cells enter the so-called crisis state, during which short 
telomeres contribute to genomic instability. Recent work has 
unraveled how dysfunctional telomeres govern cell fate during 
senescence, crisis, and transformation in human cells. Replica-
tive senescence is triggered when at least five telomeres become 
dysfunctional, a critical damage threshold to elicit a DDR char-
acterized by p53 activation (Fig. 3, A and B; Kaul et al., 2011). 
At that point, named the intermediate telomere state, telomeres 
are too short to be fully functional and are presumably unable 
to form the T-loop structure but retain sufficient protective shel-
terin to inhibit end-to-end fusions (Cesare et al., 2009, 2013; 
Kaul et al., 2011; Cesare and Karlseder, 2012). Upon loss of 
p53 and retinoblastoma protein (Rb), cells bypass senescence 
and continue to grow despite having more than five G1-phase 
intermediate state telomeres, experiencing further telomere 
shortening and entering the uncapped state, when they do not 
retain any protective properties and fuse (Fig. 3 C). A few fused 
telomeres is sufficient to lead to spindle assembly checkpoint–
independent mitotic arrest, during which telomere dysfunction 
is amplified through Aurora B–dependent removal of TRF2, 
causing cell death during crisis, a second proliferative barrier 
(Fig. 3 D; Hayashi et al., 2012, 2015). Cell death in mitosis, also 
known as mitotic catastrophe (MC), occurs as a consequence 
of failure to complete mitosis. MC is driven by a complex and 
poorly understood signaling cascade that antecedes apoptosis, 
necrosis, senescence, or autophagy (Levine and Kroemer, 2008; 
Vitale et al., 2011). The molecular mechanisms that underlie 
MC, especially those that sense mitotic failure to engage the 
apoptotic, autophagy, or necrotic machinery, remain to be elu-
cidated. It is tempting to speculate that structural and epigenetic 
changes experienced by multicentric chromosomes could serve 
as the signal for MC induction. Cell death during crisis thereby 
constitutes the second blockade against transformation in cells 
that bypassed the first barrier of senescence (Fig. 3 D). Reac-
tivation of either telomerase activity or the alternative length-
ening of telomeres (ALT) allows these premalignant cells to 
escape crisis, undergo unlimited divisions (immortalization), 
and evolve into a fully transformed cancerous state (Fig. 3 E; 
Pickett and Reddel, 2015; Shay, 2016). Indeed, ∼90% of human 
cancers present telomerase activity (Kim et al., 1994). To date, 
several mechanisms underlying reactivation of telomerase in 
cancer cells have been described: notably, mutations in TERT 
promoter, alterations in the alternative splicing of TERT pre-
mRNA, gene amplification, epigenetic changes, alterations in 
regulatory factors, and /or disruption of TPE (Jafri et al., 2016). 
Whether telomerase reactivation is an early or late event during 
tumorigenesis is still a debated question. Recent data show-
ing that TERT promoter mutations are found at early stages 
of carcinogenesis in most tumor types support the hypothesis 
that telomerase reactivation occurs at early time points during 
neoplastic transformation (Kinde et al., 2013; Allory et al., 
2014; Hurst et al., 2014; Baerlocher et al., 2015; Chan et al., 
2015; Huang et al., 2015; Tefferi et al., 2015; Jafri et al., 2016). 
However, it is still under debate whether telomerase or ALT re-
activation is the driver or simply a facilitator of postcrisis cell 
growth. It is possible that other molecular events may be re-
quired to facilitate the escape from crisis. Studies on telomere 
dynamics and karyotype analyses in a broad range of human 
tumor types at early stages underpin telomere crisis as a key 
event driving genomic instability and clonal evolution during 
progression to malignancy (Shih et al., 2001; Meeker et al., 
2004; Lin et al., 2010; Davoli and de Lange, 2011; Roger et 
al., 2013). Fused chromosomes in postcrisis cells lead to large-
scale genomic rearrangements through breakage-fusion-bridges 
cycles (B-F-B), aneuploidy, tetraploidization, nonreciprocal 
translocations, chromothripsis, and kataegis, which promote ac-
quisition of oncogenic mutations and malignant traits required 
for a fully malignant phenotype (Artandi and DePinho, 2010; 
Martínez and Blasco, 2010; Davoli and de Lange, 2012; Ma-
ciejowski et al., 2015).
Mouse models for telomere-driven cancer 
development
In vivo studies with transgenic mouse models of telomere dys-
function in combination with loss-of-function mutations in 
tumor suppressor genes strongly underscore the statement that 
telomere dysfunction leads to genomic rearrangements that 
are permissive for cancer initiation and progression (Table 2; 
Martínez and Blasco, 2011). Thus, mice doubly deficient for 
p53 and telomerase, the Terc−/− p53−/− mouse model, present a 
reduced tumor latency compared with single p53−/− mice, and 
Terc−/− p53+/− mice are prone to develop epithelial cancers typ-
ically observed in older humans (Chin et al., 1999). In addi-
tion, deficiency in the mismatch repair protein MSH2 abolishes 
the tumor-suppressor effects of short telomeres and prevents 
degenerative pathologies in Terc−/− Msh2−/− mice (Martinez et 
al., 2009a). Similarly, and despite the fact that constitutive de-
letion of either Trf1 or Pot1a results in embryonic lethality, tis-
sue-specific conditional deletion of these genes in combination 
with p53-null mutation leads to tumorigenesis (Martínez et al., 
2009b; Pinzaru et al., 2016). Thus, Trf1lox/lox K5-cre p53−/− mice 
lacking TRF1 in stratified epithelia spontaneously develop inva-
sive and genetically unstable squamous cell carcinomas in the 
tail and ear skin (Martínez et al., 2009b). Depletion of POT1a 
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Figure 3. Impact of telomere shortening on aging-associated diseases, telomeropathies, and cancer. (A) Young, healthy cells contain long, fully protected 
telomeres that progressively shorten with increased cell divisions because of the end replication problem, replication fork collapse, nucleolytic processing, 
and oxidative stress. This progressive telomere shortening eventually leads to some critically short deprotected telomeres that have been termed interme-
diate-state telomeres. In this intermediate state of deprotection, telomeres retain enough shelterin to inhibit fusions but induce a DDR characterized by 
formation of the so-called telomere-induced focus (TIF). Replicative senescence is triggered when at least five telomeres become dysfunctional (more than five 
telomere-induced focuses), a critical damage threshold to elicit a DDR characterized by p53 activation. Telomere attrition in stem cell compartments impairs 
their tissue and self-renewal capacity and is considered to be one of the primary molecular causes of aging and the onset of aging-associated diseases. 
(B) Telomeropathies or telomere syndromes develop when telomere attrition occurs prematurely as a consequence of germline mutations in genes coding 
for factors involved in telomere maintenance and repair. Successive telomere shortening across generations exhibits genetic anticipation, whereby diseases 
show a progressively earlier age of onset and an aggravation of symptoms. (C) Senescence can be bypassed by acquisition of loss-of-function mutations 
in p53 and p16/Rb tumor suppressor genes that permit further proliferation during a period of time that has been named the extended life span period, 
during which cells experience further telomere shortening, eventually entering the uncapped state, when they do not retain any protective properties and 
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and p53 in common lymphoid progenitor cells, Pot1alox/lox 
p53lox/lox hCD2-iCre mice, induces genetic instability, acceler-
ates the onset, and increases the severity of T cell lymphomas 
(Table 2; Pinzaru et al., 2016). Similarly, simultaneous inacti-
vation of Pot1a and p53 in endometrial epithelium, Pot1alox/lox 
p53lox/lox Sprr2f-Cre mice, results in invasive metastatic endome-
trial adenocarcinomas presenting nuclear atypia and tetraploid 
genomes (Akbay et al., 2013). In line with defects in shelterin 
components as drivers of genome instability, mice harboring a 
hypomorphic mutation in TPP1 in a p53−/− background show 
increased carcinomas (Else et al., 2009). Interestingly, complete 
TPP1 and p53 abrogation in stratified epithelia, the Tpp1lox/lox 
K5-cre p53−/− mouse model, does not lead to epithelial carcino-
mas, most likely because TPP1 is required to recruit telomerase 
to chromosome ends, mimicking the tumor-resistant phenotype 
of telomerase-deficient mice (Table 2; Tejera et al., 2010).
It should be noted that similar mutations in a different 
genetic context give rise to opposing outcomes resulting in 
cancer phenotype suppression. For example, late generation of 
mice doubly deficient for telomerase and the tumor suppres-
sor INK4a/ARF, Terc−/− Ink4a/Arf−/− mice, show a cancer sup-
pression phenotype and increase survival (Khoo et al., 2007). 
Trf1lox/lox p53−/− K-RasLSLG12V mice constitute an example of 
shelterin depletion as a cancer protective mechanism. Thus, si-
multaneous expression of K-RASG12V and TRF1 depletion upon 
Cre recombinase expression in the lungs impairs the growth of 
lung carcinomas and increases mouse survival independently 
of telomere length (Table  2; García-Beccaria et al., 2015). 
These studies clearly revealed that the neoplastic outcome of 
telomere dysfunction depends on the status of the DNA dam-
age surveillance mechanisms, acting oncogenes, as well as on 
tissue-specific factors.
Role of shelterins in human cancer 
development and progression
Mutations in shelterin components have also been found in can-
cer. Several studies have reported up-regulation of the shelterin 
complex TRF1 and TRF2 in lung, gastric, breast, and renal can-
cers, suggesting that their overexpression might confer prolifer-
ative advantages to tumor cells (Miyachi et al., 2002; Saito et 
al., 2002; Nakanishi et al., 2003; Diehl et al., 2011; Pal et al., 
2015). However, the role of TRF1 and TRF2 in cancer develop-
ment and progression is still unknown. One possible explana-
tion could be that high level of TRF2 in tumor cells decreases 
their ability to recruit and activate natural killer cells, thereby 
contributing to the bypass of innate immunosurveillance (Bi-
roccio et al., 2013). Interestingly, TRF1 is highly expressed in 
pluripotent stem cells and adult stem cells (Boué et al., 2010; 
Varela et al., 2011; Schneider et al., 2013). TRF1 is essential for 
both induction and maintenance of pluripotency in a telomere 
length–independent manner (Schneider et al., 2013). TRF1 is a 
direct transcriptional target of the pluripotency factor OCT3/4, 
which binds the TRF1 promoter to up-regulate TRF1 expression, 
providing a mechanistic link between TRF1 and pluripotency 
(Schneider et al., 2013). Although TRF1 is clearly essential 
for IPSC generation and the maintenance of pluripotency, the 
mechanisms by which TRF1 impacts stemness and carcinogen-
esis have yet to be elucidated. It is tempting to speculate that 
TRF1 favors the proliferative capacity of stem and cancer cells.
Mutations in the shelterin component POT1 that disrupt 
proper telomere capping and result in telomere aberrations have 
been linked to familial melanoma, familial glioma, Li-Frau-
meni–like syndrome, mantle cell lymphoma, parathyroid ade-
noma, and chronic lymphocytic leukemia (Newey et al., 2012; 
Ramsay et al., 2013; Bainbridge et al., 2014; Robles-Espinoza 
et al., 2014; Shi et al., 2014; Zhang et al., 2014; Calvete et al., 
2015). Importantly, all the identified POT1 variants conferred a 
telomere-lengthening effect, suggesting that telomere elongation 
in combination with the telomere aberrations induced by these 
mutations favors tumor development. Introduction of POT1 
mutations found in cutaneous T cell lymphoma in human and 
mouse cells showed that inhibition of POT1 results in defective 
telomere replication caused by impaired CST (CTC1-STN1-
TEN1) function at telomeres and activates ATR-dependent 
DNA damage signaling (Pinzaru et al., 2016). Attenuation of 
the ATR kinase pathway allows cancer cells lacking POT1 to 
proliferate, suggesting that POT1-mediated tumorigenesis may 
be accompanied by concomitant compensatory mechanisms 
that down-regulate the ATR-dependent DDR (Pinzaru et al., 
2016). It is intriguing that specific POT1 variants give rise to 
different cancer types. Future work warrants elucidation of the 
molecular mechanisms that determine the specificity of certain 
specific disease-associated mutations in shelterin components.
Mutations in TPP1 and RAP1 have also been found to be 
associated with familial melanoma (Aoude et al., 2014). In ad-
dition, families carrying TPP1 and RAP1 mutations were en-
riched with other cancer types, suggesting that these variants 
also cause predisposition to a broader spectrum of tumors than 
just melanoma. Although the telomeric phenotypes induced 
by these mutations have not been addressed, the observation 
that four of the five mutations found in TPP1 clustered in the 
POT1-binding domain suggests that POT1 recruitment to telo-
meres is disrupted, thereby causing similar phenotypes as ob-
served in POT1 variants discussed earlier (Liu et al., 2004). More 
intriguing is the finding of RAP1 variants co-segregating with 
melanoma because RAP1 is dispensable for telomere function 
(Martinez et al., 2010; Sfeir et al., 2010). A possible explanation 
for the role of RAP1 in cancer could be either through its role in 
repressing homology-directed repair at telomeres (Martinez et 
al., 2010; Sfeir et al., 2010) or through its role in telomere main-
tenance in the absence of telomerase (Martínez et al., 2016).
Telomeres as anticancer targets
Given that most tumors (85–90%) present telomerase activity, 
whereas telomerase is absent in most normal tissues, or is strictly 
regulated in transient-amplifying stem cells, inhibition of telo-
merase is an attractive target for cancer therapy (Kim et al., 
1994; Shay, 2016). Different approaches have been designed in 
the search for telomerase inhibitors: small-molecule inhibitors, 
antisense oligonucleotides, G-quadruplex stabilizers, immu-
fuse. (D) Fused telomeres lead to a mitotic arrest checkpoint during which telomere dysfunction is amplified by Aurora B–dependent TRF2 removal, causing 
cell death through apoptosis, necrosis, or autophagy in crisis, a second proliferative barrier that protects against tumor development. (E) Reactivation of 
either telomerase activity or ALT in some very rare crisis cells allows these premalignant cells to escape crisis and divide unlimitedly (immortalization). Fused 
chromosomes in postcrisis cells lead to large-scale genomic rearrangements that promote acquisition of oncogenic mutations and malignant traits required 
for a fully malignant phenotype, cancer.
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notherapy, gene therapy using telomerase promoter-driven ex-
pression of a suicide gene, and chemicals that block telomerase 
biogenesis (Harley, 2008; Agrawal et al., 2012; Buseman et al., 
2012; Jafri et al., 2016). Among all antitelomerase compounds 
developed, the oligonucleotide imetelstat (GRN163L) appears 
to be the most promising telomerase inhibitor and the one most 
extensively evaluated in clinical trials. Imetelstat sequence 
binds to a complementary oligonucleotide region of hTR at the 
active site of telomerase holoenzyme, leading to complete inhi-
bition of enzyme activity (Fig. 2; Jafri et al., 2016). However, 
inhibition of telomere maintenance by targeting telomerase in 
cancer has showed effectiveness in only some myeloid tumors 
but has largely failed in solid tumors (Baerlocher et al., 2015; 
Tefferi et al., 2015; Jafri et al., 2016). The reasons underlying 
the lack of success are likely that therapeutic strategies based 
on telomerase inhibition to treat cancer will be effective only 
when telomeres shorten below a minimum length, implying a 
long lag period before cell death. Indeed, telomerase activity 
is dispensable for transformation of cells with long telomeres 
(Seger et al., 2002), and studies with telomerase inhibitors indi-
cate that they are effective preferentially in cells with short telo-
meres (Wang et al., 2004; Buseman et al., 2012). In line with 
this idea, telomerase abrogation in the context of cancer-prone 
mouse models, including the K-Ras+/G12D lung tumorigene-
sis mouse model, showed antitumorigenic activity only after 
several mouse generations in the absence of telomerase when 
telomeres reached a critically short length (Chin et al., 1999; 
Greenberg et al., 1999; González-Suárez et al., 2000; Perera 
et al., 2008). Moreover, these antitumorigenic effects of short 
telomeres owing to telomerase deficiency are abrogated in the 
absence of p53 (Chin et al., 1999).
Alternative therapeutic approaches that target telomeres in 
a telomere length–independent manner are starting to emerge. 
In contrast to telomerase inhibition, telomere uncapping has 
been shown to cause rapid induction of cell death and/or senes-
cence in a manner that is independent of telomerase activity and 
telomere length (Karlseder et al., 1999; Martínez et al., 2009b). 
Thus, given that telomere dysfunction can be achieved inde-
pendently of telomere length, telomere uncapping strategies 
emerge as a more universal way to rapidly impair the growth of 
dividing cells. One of these alternative approaches consists of 
a telomere-targeted telomerase-dependent potential anticancer 
therapy that uses a nucleoside analogue, 6-thio-2′-deoxygua-
nosine (6-thio-dG). 6-Thio-dG is recognized by telomerase 
and incorporated into de novo synthesized telomeres, leading 
to telomere dysfunction solely in telomerase-expressing cells 
(Fig. 2). Treatment with 6-thio-dG leads to rapid cell death in 
most of the cancer cell lines assayed and to telomere dysfunc-
tion in in vivo xenograft models (Mender et al., 2015). Target-
ing telomerase recruitment to telomeres has also been proposed 
as a potential anticancer treatment (Nakanishi et al., 2003).
We have recently developed a novel telomerase-inde-
pendent and telomere length–independent strategy to induce 
telomere dysfunction by targeting TRF1 (Fig.  2; García-Bec-
caria et al., 2015). Genetic Trf1 deletion impaired the growth of 
p53-null KRas(G12V)-induced lung carcinomas and increased 
mouse survival independently of telomere length. Chemical 
inhibition of TRF1 binding to telomeres by small molecules 
blocked the growth of already established lung carcinomas by 
inducing a rapid DDR and without affecting mouse survival 
or tissue function, supporting induction of acute telomere un-
capping as a promising therapeutic target for lung cancer and 
very likely for many other cancer types (García-Beccaria et al., 
2015). Chemical inhibition of TRF2 dimerization has also been 
achieved by targeted peptide synthesis that directly binds to the 
TRFH dimerization domain of TRF2 (Di Maro et al., 2014). 
Treatment of HeLa cells with TRF2-binding chemotypes did 
not affect TRF2 telomeric localization but induced rapid DDR 
activation, end-to-end fusions, and cell death indicative of 
telomere dysfunction (Di Maro et al., 2014). Although further 
clinical research is needed to ultimately address the efficacy 
of telomere-uncapping chemical inhibition in human cancer, 
these strategies provide novel opportunities for the develop-
ment of anticancer agents.
Outstanding questions in telomere-related 
diseases and cancer
Although telomere biology has been extensively studied, our 
knowledge of the implications of telomeres and telomere pro-
teins in human disease has considerably improved in recent 
years. Current research efforts focus on how our knowledge of 
telomere biology and its connection with human disease can be 
translated into the clinic to improve human health. Although 
some telomere-based therapies have already reached clinical 
trials, the path is still long. The fact that telomere dysfunc-
tion may have different and even opposing outcomes in aging 
and cancer makes the goal of developing telomere-based anti- 
aging and anticancer therapies a delicate challenge that re-
quires a highly controllable technology. Results obtained in 
mouse models with telomerase gene therapy as a treatment for 
aging-associated diseases and telomere syndromes, as well as 
shelterin chemical inhibition as anticancer therapy treatment, 
constitute promising opportunities for further clinical develop-
ment. However, additional studies are needed to determine the 
Table 2. Examples of mouse models underscoring telomere dysfunction as either a driving force in cancer development or as a cancer suppressor
Genotype Cancer phenotype Reference
Terc−/− p53−/−       Earlier onset lymphoma/sarcoma, epithelial carcinoma Chin et al., 1999
Terc−/− Msh2−/−       Lymphoma/carcinoma Martinez et al., 2009a
Trf1lox/lox K5-cre p53−/−       Squamous cell carcinoma Martínez et al., 2009b
Pot1alox/lox p53lox/lox hCD2-iCre       T cell lymphomas Pinzaru et al., 2016
Pot1alox/lox p53lox/lox Sprr2f-Cre       Endometrial adenocarcinomas Akbay et al., 2013
Tpp1Acd p53−/−       Carcinomas Else et al., 2009
Tpp1lox/lox K5-cre p53−/−       Cancer suppressor Tejera et al., 2010
Terc−/− Ink4a/Arf−/−       Delayed lymphoma/fibrosarcoma onset Khoo et al., 2007
Trf1lox/lox p53−/− K-RasLSLG12V       Growth impairment of lung carcinoma García-Beccaria et al., 2015
The effects of telomere dysfunction in cancer-prone mouse models depend on the status of DNA damage surveillance mechanisms, acting oncogenes, and tissue-specific factors.
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undesired long-term effects associated with exogenous reex-
pression of telomerase and shelterin inhibition.
The molecular mechanisms underlying the specificity of 
certain specific disease-associated mutations/variants in shelter-
ins are yet an open field of research. For example, specific POT1 
variants give rise to chronic lymphocytic leukemia, whereas 
other amino acid substitutions predispose to familial melanoma, 
cardiac angiosarcomas, or gliomas. Several shelterin mutations 
associated with different tumor types have recently been found, 
and presumably many more shelterin mutations are yet to be 
identified in human cancer. These observations further support 
the use of shelterins as cancer targets and raise the question of 
the potential translational applications of shelterin gene therapy 
as preventive treatment in mutation carriers.
In summary, the works discussed in this review provide 
proof of concept for the feasibility of telomere-targeted thera-
peutic approaches for the prevention and treatment of telomere 
dysfunction–mediated diseases in animal models and pave the 
way for their development and implementation in the clinic.
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